Cartesian Therapeutics (RNAC) Receivables: 2015-2025
Historic Receivables for Cartesian Therapeutics (RNAC) over the last 7 years, with Sep 2025 value amounting to $722,000.
- Cartesian Therapeutics' Receivables fell 87.57% to $722,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 93.19%. This contributed to the annual value of $872,000 for FY2024, which is 90.15% down from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Receivables is $722,000, which was up 103.95% from $354,000 recorded in Q2 2025.
- Cartesian Therapeutics' Receivables' 5-year high stood at $35.5 million during Q2 2024, with a 5-year trough of $354,000 in Q2 2025.
- In the last 3 years, Cartesian Therapeutics' Receivables had a median value of $5.8 million in 2024 and averaged $7.3 million.
- Its Receivables has fluctuated over the past 5 years, first soared by 451.41% in 2024, then tumbled by 99.00% in 2025.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Receivables stood at $9.9 million in 2021, then fell by 1.57% to $9.8 million in 2022, then fell by 9.29% to $8.9 million in 2023, then plummeted by 90.15% to $872,000 in 2024, then plummeted by 87.57% to $722,000 in 2025.
- Its Receivables stands at $722,000 for Q3 2025, versus $354,000 for Q2 2025 and $1.8 million for Q1 2025.